•  
  •  
 

Publication Date

2-28-2014

Keywords

melanoma, targeted therapy, NRAS

Abstract

The development and regulatory approval of vemurafenib and dabrafenib for metastatic melanoma patients with activating BRAF mutations has demonstrated that personalized targeted therapy strategies can provide significant clinical benefit in this highly aggressive disease. However, these agents are not beneficial in patients who do not have activating BRAF mutations, representing over half of all melanoma patients. Recent studies have demonstrated that melanomas have the highest rate of somatic mutations among the major cancers. Based on this information, additional personalized treatment strategies are now in various stages of clinical development and testing. These efforts are being guided by the lessons learned in the development of effective therapeutics for BRAF, as well as a growing understanding of the molecular heterogeneity and drivers of this disease.

Included in

Oncology Commons

Share

COinS
 

Submitted

March 17th, 2014

Accepted

May 22nd, 2014

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.